India’s first indigenous mRNA vaccine for the Omicron variant, GEMCOVAC-OM, developed by Pune-based Gennova Biopharmaceuticals Ltd, was approved under emergency use guidelines by the Drug Controller General of India .
This comes a year after the company got approval for GEMCOVAC-19, the country’s first m-RNA vaccine against COVID-19.
The vaccine is the first booster Covid-19 vaccine developed in India against the highly transmissible Omicron variant and has demonstrated robust immune responses in phase 3 clinical trials.
It is stable at two to eight degrees Centigrade and has been developed using Gennova's indigenous platform technology, supported under 'Mission Covid Suraksha'.
The Indian ‘Covid-19 Vaccine Development Mission’ by DBT’s dedicated mission implementation unit at BIRAC, for further clinical development and scale-up of the prototype vaccine, which received EUA on June 29, 2022.”
